Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tepotinib TF3 100 mg vs 250 mg Tablets
NCT04204902Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity and 1 more. Started Oct 2019; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04204902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204902.